How should modern analytical development be conducted?
Recommendation

3/4 February 2026
Evaluation, Implementation and Use of Suitable Technologies
In 2017, the board of the ECA Foundation's Analytical Quality Control Group (AQCG) has decided to strengthen the lifecycle approach for analytical procedures. Therefore, the Group developed a new guideline on "Analytical Procedure Lifecycle Management".
The draft for this guideline was discussed with the participants of the Analytical Procedure Lifecycle Management Conference on 23/24 November, 2017 in Vienna. The conference objective was to collect proposals and suggestions for the final version of this guideline. Meanwhile, the ECA QC Group has considered the received suggestions and implemented them as far as possible.
The AQCG is currently in the process of finalizing the final Version 1.0.
In this comprehensive Analytical Procedure Lifecycle Management guideline, the following points are presented and discussed:
- Key References
- Quality involvement/Responsibilities
- Rationale for this Guideline
- Principles of Analytical Procedure Lifecycle Management (APLM)
- Prerequisites for the APLM
- Guidance recommendations for the 3 stages of the APLM
- Stage 1: Procedure Design and Development
- Procedure development and gaining understanding
- Establishing an Analytical Control Strategy
- Establishing a Replication Strategy
- Stage 2: Procedure Performance Qualification
- Stage 3: Procedure Performance Verification
- Technical Glossary
The final Version 1.0 of this guideline will be presented at the ECA APLM Workshop on 20 November 2018 as part of the PharmaLab Congress 2018 in Düsseldorf/Neuss in Germany. Each participant will receive a copy of this important new APLM document, and thereby an important tool for implementing a lifecycle approach to analytical development in one's own company.
Related GMP News
15.12.2025FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory
15.12.2025FDA Warning: No Recall Conducted Despite Confirmed Benzene Impurity
10.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
26.11.2025FDA Warning Letter Highlights Deficiencies in SST and HPLC Practices
13.11.2025Proposed Revision of USP <1225> Published in the Pharmacopeial Forum


